Welcome to our dedicated page for Predictive Oncology SEC filings (Ticker: POAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Predictive Oncology’s SEC disclosures can feel like running a clinical trial of your own—hundreds of pages on AI-driven drug screens, biobank valuations, and FDA-regulated devices. Whether you’re tracking STREAMWAY revenue or the PEDAL platform’s impact on R&D spend, the details hide deep inside 10-K footnotes and 8-K exhibits.
Stock Titan solves that problem. Our AI-powered summaries translate each Predictive Oncology annual report 10-K simplified, every quarterly earnings report 10-Q filing, and each Predictive Oncology 8-K material events explained into clear, actionable language. Need real-time alerts? We surface Predictive Oncology Form 4 insider transactions in real time, flagging executive stock sales before they hit the news. The platform covers the full spectrum—proxy statement executive compensation tables, registration statements, and even niche S-8 filings—updated the minute EDGAR posts.
Looking for specific answers? Use our search prompts like “understanding Predictive Oncology SEC documents with AI” or “Predictive Oncology earnings report filing analysis” and jump straight to AI-generated highlights: segment revenue trends, cash runway projections, and risk-factor changes. Monitor Predictive Oncology insider trading Form 4 transactions, compare R&D outlays quarter-over-quarter, or download clean tables for your own models. With comprehensive filing coverage, plain-English explanations, and machine-learning insights, Stock Titan turns complex biotech disclosures into practical intelligence investors actually use.
Predictive Oncology insider grant and holdings summary
Director Daniel E. Handley was granted 64,680 restricted stock units (RSUs) on 09/09/2025. Each RSU converts to one share of common stock upon vesting, and the award is scheduled to vest in full on October 31, 2025, subject to continued service through that date. The RSUs were granted at a recorded price of $0.00. Following the grant, the reporting person beneficially owns 81,698 shares. The Form 4 indicates a single reporting person filed for this transaction.
Predictive Oncology Inc. (POAI) reported a non‑derivative grant to director Matthew Hawryluk consisting of 64,680 restricted stock units (RSUs) on 09/09/2025. Each RSU converts into one share of common stock upon vesting. The RSUs are scheduled to vest in full on October 31, 2025, contingent on continued service through that date. After the grant, Mr. Hawryluk is recorded as beneficially owning 74,168 shares of common stock. The Form 4 was signed by an attorney‑in‑fact on behalf of the reporting person on 09/11/2025.
Predictive Oncology Inc. (POAI) director Veena Rao was granted 64,680 restricted stock units (RSUs) on 09/09/2025. Each RSU converts to one share of common stock on vesting, and the grant was recorded at a $0.00 acquisition price. Following the award, Ms. Rao's reported beneficial ownership increased to 73,797 shares. The RSUs are scheduled to vest in full on October 31, 2025, subject to continued service through the vesting date. The filing identifies the transaction as an acquisition by the reporting person in their capacity as a director and shows the report was submitted by one reporting person.
Predictive Oncology Inc. director Gregory St. Clair Sr. was granted 64,680 restricted stock units (RSUs) on 09/09/2025. Each RSU converts to one share upon vesting and the grant carries a $0.00 purchase price. The RSUs vest in full on October 31, 2025, subject to continued service through that date. After the grant, the reporting person is shown as beneficially owning 85,882 shares. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 09/11/2025.
Predictive Oncology Inc. (POAI) director Charles Lee Nuzum Sr. received a grant of 64,680 restricted stock units (RSUs) on 09/09/2025, according to this Form 4 filing. Each RSU represents the right to one share of common stock upon vesting. The RSUs are scheduled to vest in full on October 31, 2025, subject to continued service through that date. After the grant, the reporting person beneficially owns 94,587 shares. The filing indicates it was made by one reporting person and was signed via attorney-in-fact on 09/11/2025.
Predictive Oncology Inc. (POAI) reported a Form 4 showing that Joshua Blacher, serving as Interim CFO and an officer/director, was granted 97,000 restricted stock units (RSUs) on 09/09/2025. Each RSU represents the right to one share of common stock on vesting. The RSUs vest in full on October 31, 2025, subject to continued service through that date. Following the grant, Mr. Blacher is recorded as beneficially owning 97,000 shares directly from this award. The filing is signed 09/11/2025.
Predictive Oncology Inc. (POAI) reporting person Raymond F. Vennare, who serves as Chief Executive Officer and a director, received a grant of 124,959 restricted stock units (RSUs) on 09/09/2025. Each RSU converts to one share of common stock upon vesting. The RSUs are scheduled to vest in full on October 31, 2025, subject to continued service through that date. Following the grant, the reporting person beneficially owns 132,081 shares of common stock as of the reported transaction. The Form 4 was signed on 09/11/2025 by an attorney-in-fact.
Joshua Blacher, identified as Interim CFO and an officer of Predictive Oncology Inc. (POAI), filed an initial Form 3 disclosing that he does not beneficially own any securities of the issuer. The report lists the relevant event date as 10/01/2023 and includes a signed remark that the Form 3 is being filed late due to an inadvertent administrative oversight; the filer states he is submitting the form promptly upon discovery and intends to comply with future Section 16(a) filing requirements. No non-derivative or derivative holdings are reported on this form.
FAQ
What is the current stock price of Predictive Oncology (POAI)?
What is the market cap of Predictive Oncology (POAI)?
